MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, announced on June 16, 2025, that it has submitted an Investigational New Drug $(IND.AU)$ application to the U.S. Food and Drug Administration (FDA) for its novel drug, MBX 4291. This long-acting GLP-1/GIP receptor co-agonist prodrug is designed for the treatment of obesity and is expected to initiate a Phase 1 trial in the third quarter of 2025. The drug, developed using MBX's proprietary PEP™ platform technology, aims to provide a once-monthly injectable solution with improved tolerability and adherence. This submission marks a significant step in MBX's efforts to offer innovative treatments for endocrine and metabolic disorders.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.